The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia

  • STATUS
    Recruiting
  • participants needed
    18
  • sponsor
    Institute of Hematology & Blood Diseases Hospital
Send
Updated on 5 August 2020
See if I qualify
rituximab
anemia
ibrutinib

Summary

This is an open-label, single-arm study to evaluate the safety and efficacy of Ibrutinib in subjects with refractory/relapsed autoimmune hemolytic anemia.

Details
Condition Refractory/Relapsed Autoimmune Hemolytic Anemia
Age 6years - 70years
Treatment Ibrutinib
Clinical Study IdentifierNCT04398459
SponsorInstitute of Hematology & Blood Diseases Hospital
Last Modified on5 August 2020

Eligibility

 Yes No Not Sure

Inclusion Criteria

ECOG 3
Age from 6 to 70
Diagnosed with WAIHA or MAIHA
Meets the criteria of relapsed / refractory AIHA
Meets the criteria of DAT-negative AIHA without any other inherited or acquired hemolytic diseases, and previously treated effectively with glucocorticoids and rituximab
Signed informed consent
Organs in good function

Exclusion Criteria

Nursing woman
Active bacterial, virus, fungal or parasitic infection, including HIV infection, HbsAg and HBV DNA positive, HCV DNA positive, etc
Diagnosed with cold agglutinin disease or cold agglutinin syndrome or paroxysmal cold hemoglobinuria
Secondary AIHA caused by drugs or infection
Received rituximab in 8 weeks before enrollment
Previously received treatment with BTK inhibitor
Previously received organ or stem cell transplantation
Have a history of thrombosis or organ infarction
Diagnosed with an active stage of connective tissue disease
Have a history of lymphoproliferative tumors or any other malignant tumors
Have other inherited or acquired hemolytic diseases
Received low-molecular-weight heparin or warfarin within 1 week before enrollment or during the Ibrutinib treatment
Received CYP3A4 Enzyme Inhibitors or Inducers within 1 week before enrollment or during the Ibrutinib treatment
Have a history of mental illness
Inability to understand or to follow study procedures
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

rituximab
anemia
ibrutinib

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.